Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 19;11(16):4866.
doi: 10.3390/jcm11164866.

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Megan L Sulciner  1 , Stanley W Ashley  1   2 , George Molina  1   2
Affiliations
Review

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Megan L Sulciner et al. J Clin Med. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies in the United States. Improvements in imaging have permitted the categorization of patients according to radiologic involvement of surrounding vasculature, i.e., upfront resectable, borderline resectable, and locally advanced disease, and this, in turn, has influenced the sequence of chemotherapy, surgery, and radiation therapy. Though surgical resection remains the only curative treatment option, recent studies have shown improved overall survival with neoadjuvant chemotherapy, especially among patients with borderline resectable/locally advanced disease. The role of radiologic imaging after neoadjuvant therapy and the potential benefit of adjuvant therapy for borderline resectable and locally advanced disease remain areas of ongoing investigation. The advances made in the treatment of patients with borderline resectable/locally advanced disease are promising, yet disparities in access to cancer care persist. This review highlights the significant advances that have been made in the treatment of borderline resectable and locally advanced PDAC, while also calling attention to the remaining challenges.

Keywords: borderline resectable; cancer care disparities; locally advanced; neoadjuvant therapy; pancreatic ductal adenocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. GBD 2017 Pancreatic Cancer Collaborators The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2019;4:934–947. doi: 10.1016/S2468-1253(19)30347-4. - DOI - PMC - PubMed
    1. Bengtsson A., Andersson R., Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci. Rep. 2020;10:16425. doi: 10.1038/s41598-020-73525-y. - DOI - PMC - PubMed
    1. Callery M.P., Chang K.J., Fishman E.K., Talamonti M.S., William Traverso L., Linehan D.C. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann. Surg. Oncol. 2009;16:1727–1733. doi: 10.1245/s10434-009-0408-6. - DOI - PubMed
    1. Katz M.H.G., Pisters P.W.T., Evans D.B., Sun C.C., Lee J.E., Fleming J.B., Vauthey J.N., Abdalla E.K., Crane C.H., Wolff R.A., et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J. Am. Coll. Surg. 2008;206:833–846. doi: 10.1016/j.jamcollsurg.2007.12.020. discussion 846. - DOI - PMC - PubMed
    1. Tempero M.A., Malafa M.P., Al-Hawary M., Behrman S.W., Benson A.B., Cardin D.B., Chiorean E.G., Chung V., Czito B., Del Chiaro M., et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 2021;19:439–457. doi: 10.6004/jnccn.2021.0017. - DOI - PubMed

LinkOut - more resources